Influence of the new phosphodiesterase inhibitor roflumilast (B9302-107) on cardiovascular function after repeated oral sid administration in healthy male volunteers. A double-blind randomized placebo-controlled cross-over study
Study Complete
Official Title
*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
-
Sex
Male
Actual Enrollment
13
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Feb 1997
Primary Completion Date: -
Study Completion Date: 01 Jul 1997
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jun 2016 by Takeda
Sponsors
Takeda
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
